Wenjian Yang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5891744/publications.pdf

Version: 2024-02-01

95	7,416	101543	58581
papers	citations	36 h-index	82 g-index

98	98	98	8164
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. Haematologica, 2022, 107, 371-380.	3.5	5
2	Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. Pharmacogenetics and Genomics, 2022, 32, 60-66.	1.5	7
3	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. JAMA Oncology, 2022, 8, 354.	7.1	35
4	Association between CEP72 genotype and persistent neuropathy in survivors of childhood acute lymphoblastic leukemia. Leukemia, 2022, 36, 1160-1163.	7.2	4
5	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nature Genetics, 2022, 54, 170-179.	21.4	29
6	Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2022, 114, 1287-1295.	6.3	10
7	Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Advances, 2022, 6, 3386-3397.	5.2	8
8	Race, Genotype, and Azathioprine Discontinuation. Annals of Internal Medicine, 2022, 175, 1092-1099.	3.9	14
9	Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia. Blood, 2022, 140, 1507-1521.	1.4	2
10	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. Journal of the National Cancer Institute, 2021, 113, 933-937.	6.3	9
11	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. Blood, 2021, 137, 1550-1552.	1.4	3
12	Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. Blood, 2021, 137, 364-373.	1.4	37
13	GATA3 rs3824662A allele in Bâ€cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis. American Journal of Hematology, 2021, 96, E71-E74.	4.1	5
14	Effects of NT5C2 Germline Variants on 6â€Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2021, 109, 1538-1545.	4.7	5
15	Association ofGATA3Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2021, 113, 408-417.	6.3	16
16	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature Cancer, 2021, 2, 284-299.	13.2	70
17	Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. Leukemia, 2021, 35, 3078-3091.	7.2	15
18	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. Clinical Pharmacology and Therapeutics, 2021, 110, 794-802.	4.7	7

#	Article	IF	Citations
19	Identification of small molecules that mitigate vincristineâ€induced neurotoxicity while sensitizing leukemia cells to vincristine. Clinical and Translational Science, 2021, 14, 1490-1504.	3.1	12
20	Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discovery, 2021, 11, 2846-2867.	9.4	83
21	NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir. Nature Communications, 2021, 12, 4181.	12.8	11
22	Abstract 2118: Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia. , 2021, , .		0
23	Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids. Cell Metabolism, 2021, 33, 1592-1609.e7.	16.2	15
24	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	8.2	20
25	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3476-3476.	1.4	0
26	The Impact of T Cell Immunity on Chemotherapy Response in Childhood Acute Lymphoblastic Leukemia. Blood, 2021, 138, 703-703.	1.4	0
27	Challenges in clinical implementation of CYP2D6 genotyping: choice of variants to test affects phenotype determination. Genetics in Medicine, 2020, 22, 232-233.	2.4	10
28	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28040.	1.5	38
29	Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment. Blood, 2020, 136, 2955-2958.	1.4	3
30	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 329-344.	13.2	44
31	Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5394-5401.	7.1	95
32	Pharmacogenomics of intracellular methotrexate polyglutamates in patientsâ€™ leukemia cells in vivo. Journal of Clinical Investigation, 2020, 130, 6600-6615.	8.2	18
33	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood, 2019, 134, 1227-1237.	1.4	37
34	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. Journal of Clinical Oncology, 2019, 37, 2051-2061.	1.6	61
35	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatric Blood and Cancer, 2019, 66, e27681.	1.5	8
36	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. Journal of the National Cancer Institute, 2019, 111, 1350-1357.	6.3	32

#	Article	IF	Citations
37	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nature Communications, 2019, 10, 5348.	12.8	58
38	Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. Pharmacogenomics Journal, 2019, 19, 305-314.	2.0	9
39	Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report. Haematologica, 2019, 104, 556-563.	3.5	36
40	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood, 2019, 133, 724-729.	1.4	44
41	Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children. Blood, 2019, 134, 653-653.	1.4	1
42	Association of the GATA3 rs3824662A allele with clinical outcomes in adult patients with adult B-ALL.. Journal of Clinical Oncology, 2019, 37, 7023-7023.	1.6	1
43	Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia. Blood, 2019, 134, 650-650.	1.4	0
44	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 33, 937-948.e8.	16.8	142
45	Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood, 2018, 131, 2466-2474.	1.4	43
46	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Journal of Clinical Oncology, 2018, 36, 591-599.	1.6	121
47	Multiplex assessment of protein variant abundance by massively parallel sequencing. Nature Genetics, 2018, 50, 874-882.	21.4	323
48	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. Blood, 2018, 132, 2697-2697.	1.4	2
49	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. Blood, 2018, 132, 2665-2665.	1.4	0
50	Osteonecrosis is unrelated to hip anatomy in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2017, 64, e26407.	1.5	1
51	Palmarâ€plantar erythrodysesthesia syndrome following treatment with highâ€dose methotrexate or highâ€dose cytarabine. Cancer, 2017, 123, 3602-3608.	4.1	11
52	Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood, 2017, 130, 1209-1212.	1.4	90
53	Klinefelter syndrome and 47,<scp>XYY</scp> syndrome in children with B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 179, 843-846.	2.5	4
54	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2017, 35, 2700-2707.	1.6	38

#	Article	IF	Citations
55	Reply to I.J. Cohen. Journal of Clinical Oncology, 2017, 35, 3989-3991.	1.6	2
56	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 2133-2140.	1.6	88
57	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood, 2016, 127, 558-564.	1.4	56
58	NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nature Genetics, 2016, 48, 367-373.	21.4	389
59	Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood, 2015, 126, 2896-2899.	1.4	76
60	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	1.4	110
61	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2015, 126, 1770-1776.	1.4	102
62	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nature Communications, 2015, 6, 7553.	12.8	72
63	Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2015, 313, 815.	7.4	234
64	Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2015, 33, 1235-1242.	1.6	369
65	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nature Genetics, 2015, 47, 607-614.	21.4	126
66	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncology, The, 2015, 16, 1659-1666.	10.7	161
67	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. Blood, 2015, 126, 3714-3714.	1.4	2
68	Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for Acute Lymphoblastic Leukemia. Blood, 2015, 126, 250-250.	1.4	0
69	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. Blood, 2015, 126, 695-695.	1.4	2
70	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood, 2014, 124, 1266-1276.	1.4	84
71	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. Blood, 2014, 124, 367-367.	1.4	1
72	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. Blood, 2014, 124, 63-63.	1.4	6

#	Article	IF	Citations
73	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 3722-3722.	1.4	0
74	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood, 2014, 124, 132-132.	1.4	1
75	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature Genetics, 2013, 45, 1494-1498.	21.4	264
76	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. Journal of the National Cancer Institute, 2013, 105, 733-742.	6.3	208
77	Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood, 2013, 121, 898-904.	1.4	174
78	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 60-60.	1.4	1
79	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 618-618.	1.4	6
80	ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012, 30, 751-757.	1.6	165
81	Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood, 2012, 120, 4197-4204.	1.4	103
82	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. Blood, 2012, 120, 2466-2466.	1.4	5
83	Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 878-878.	1.4	0
84	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations. Blood, 2012, 120, 877-877.	1.4	2
85	Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood, 2011, 118, 5218-5226.	1.4	180
86	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. Blood, 2011, 118, 571-571.	1.4	0
87	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Blood, 2010, 116, 8-8.	1.4	1
88	Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2009, 301, 393.	7.4	193
89	Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nature Genetics, 2009, 41, 1001-1005.	21.4	459
90	Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2009, 360, 470-480.	27.0	1,260

#	Article	IF	Citations
91	Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood, 2009, 113, 4512-4520.	1.4	52
92	Genetic Variations in GRIA1 On Chromosome 5q33 Related to Asparaginase Hypersensitivity in Childhood Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 112-112.	1.4	0
93	In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile. PLoS Medicine, 2008, 5, e83.	8.4	75
94	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation, 2005, 115, 110-117.	8.2	129
95	Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment. New England Journal of Medicine, 2004, 351, 533-542.	27.0	565